In Move to Power Precision Oncology for Patients, COTA and Genomic Testing Cooperative Form New Data Partnership
The two companies are joining forces to integrate COTA’s deep clinical oncology real-world data with GTC’s comprehensive genomics testing data.
COTA has extended its Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) for an additional three years. This renewed RCA will expand on the objective to explore the applications of real-world data in oncology.
Leveraging its past knowledge of real-world evidence applications and learnings, COTA has joined the COVID-19 Evidence Accelerator program, a joint initiative of Friends of Cancer Research (Friends) and the Reagan-Udall Foundation for the Food and Drug Administration. Through this initiative, COTA is delivering findings from its observational, real-world studies using data from over 3,000 patients hospitalized with COVID-19 within the Hackensack Meridian Health network.
Collaboration Aims to Study Variation in Cancer Treatment Patterns by Extracting and Analyzing Real-World Data